Next Article in Journal
Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte and Monocyte-to-Lymphocyte Ratio in Bipolar Disorder
Next Article in Special Issue
Etiology of ‘Sinus Headache’—Moving the Focus from Rhinology to Neurology. A Systematic Review
Previous Article in Journal
BCI Training Effects on Chronic Stroke Correlate with Functional Reorganization in Motor-Related Regions: A Concurrent EEG and fMRI Study
Previous Article in Special Issue
Localised Grey Matter Atrophy in Multiple Sclerosis and Clinically Isolated Syndrome—A Coordinate-Based Meta-Analysis, Meta-Analysis of Networks, and Meta-Regression of Voxel-Based Morphometry Studies
 
 
Article

SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease

1
Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain
2
Movement Disorder Unit, Neurology Department, Hospital Universitario Ramon y Cajal, 28034 Madrid, Spain
*
Author to whom correspondence should be addressed.
Brain Sci. 2021, 11(1), 57; https://doi.org/10.3390/brainsci11010057
Received: 11 December 2020 / Revised: 22 December 2020 / Accepted: 4 January 2021 / Published: 6 January 2021
(This article belongs to the Special Issue Collection on Clinical Neuroscience)
Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively in a Movement Disorders Unit (November 2018–February 2019). All were assessed with Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms-Urinary subscale (SCOPA-AUT-U) by the attending neurologist, and a month afterwards by an independent researcher blinded to treatment and clinical records in a routine clinical practice setting. Clinical variables were compared among patients who were prescribed safinamide (SA+) for the treatment of motor fluctuations and those with different treatment regimes (SA−). Results: From 169 patients screened initially, 54 were excluded due to severe incontinence, absence of urinary symptoms or previous safinamide treatment. Thirty-five patients were included in SA+ and 79 in SA−. Both groups were comparable in terms of clinical variables, except in basal urinary symptoms, with more severity in the SA+ group. In the follow-up assessment, total SCOPA-AUT-U, as well as urgency, incontinence, frequency and nocturia subscales improved significantly in the SA+ group, while the SA− group remained unchanged. Conclusions: Safinamide could be helpful in the improvement of urinary symptoms in PD. View Full-Text
Keywords: safinamide; urinary symptoms; Parkinson disease; nonmotor fluctuations safinamide; urinary symptoms; Parkinson disease; nonmotor fluctuations
Show Figures

Graphical abstract

MDPI and ACS Style

Gómez-López, A.; Sánchez-Sánchez, A.; Natera-Villalba, E.; Ros-Castelló, V.; Beltrán-Corbellini, Á.; Fanjul-Arbós, S.; Pareés Moreno, I.; López-Sendon Moreno, J.L.; Martínez Castrillo, J.C.; Alonso-Canovas, A. SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease. Brain Sci. 2021, 11, 57. https://doi.org/10.3390/brainsci11010057

AMA Style

Gómez-López A, Sánchez-Sánchez A, Natera-Villalba E, Ros-Castelló V, Beltrán-Corbellini Á, Fanjul-Arbós S, Pareés Moreno I, López-Sendon Moreno JL, Martínez Castrillo JC, Alonso-Canovas A. SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease. Brain Sciences. 2021; 11(1):57. https://doi.org/10.3390/brainsci11010057

Chicago/Turabian Style

Gómez-López, Ana, Arantxa Sánchez-Sánchez, Elena Natera-Villalba, Victoria Ros-Castelló, Álvaro Beltrán-Corbellini, Samira Fanjul-Arbós, Isabel Pareés Moreno, José Luis López-Sendon Moreno, Juan Carlos Martínez Castrillo, and Araceli Alonso-Canovas. 2021. "SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease" Brain Sciences 11, no. 1: 57. https://doi.org/10.3390/brainsci11010057

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop